Stock Analysis
Ansell (ASX:ANN) Full Year 2023 Results
Key Financial Results
- Revenue: US$1.66b (down 15% from FY 2022).
- Net income: US$148.3m (down 6.6% from FY 2022).
- Profit margin: 9.0% (up from 8.1% in FY 2022). The increase in margin was driven by lower expenses.
- EPS: US$1.18 (down from US$1.25 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Ansell Meets Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.
Looking ahead, revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Medical Equipment industry in Australia.
Performance of the Australian Medical Equipment industry.
The company's shares are down 1.3% from a week ago.
Risk Analysis
Be aware that Ansell is showing 1 warning sign in our investment analysis that you should know about...
Valuation is complex, but we're helping make it simple.
Find out whether Ansell is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ASX:ANN
Ansell
Designs, develops, and manufactures protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean, and North America.
Flawless balance sheet and undervalued.